Certara Corporation Conducts Model-Based Meta-Analysis To Compare The Efficacy And Tolerability Of Two Chronic Nonmalignant Pain Medications

ST. LOUIS, Mo.--(BUSINESS WIRE)--Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced today that its model-based meta-analysis comparing tramadol with tapentadol for the treatment of chronic nonmalignant pain has been published in the journal Pain and Therapy. This study provides an indirect comparison of the efficacy and tolerability profiles of the two medications. The resulting peer-reviewed paper is now available online at http://link.springer.com/article/10.1007/s40122-014-0023-5.

Help employers find you! Check out all the jobs and post your resume.